February 26, 2024
Loading...
You are here:  Home  >  'AbbVie'
Latest

Direct Relief poised to open new, larger headquarters

By   /  Friday, June 15th, 2018  /  Latest news, Nonprofits, Real Estate, South Coast  /  Comments Off on Direct Relief poised to open new, larger headquarters

This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.

Latest

Amgen settles with AbbVie over Humira biosimilar litigation

By   /  Friday, October 6th, 2017  /  East Ventura County, Health Care & Life Science, right, Technology  /  Comments Off on Amgen settles with AbbVie over Humira biosimilar litigation

This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.

Latest

Amgen settles with AbbVie over Humira biosimilar

By   /  Thursday, September 28th, 2017  /  East Ventura County, Health Care & Life Science, Latest news, Technology  /  Comments Off on Amgen settles with AbbVie over Humira biosimilar

Thousand Oaks biopharmaceutical giant Amgen announced Sept. 28 that it had reached a settlement with Chicago-based competitor AbbVie, which had sued to block Amgen’s Humira biosimilar Amjevita. The rheumatoid arthritis and inflammation treatment received U.S. Food and Drug Administration approval in September of 2016, but sales were blocked when AbbVie filed a patent infringement claim Read More →

Latest

Amgen gets European approval for biosimilar of Humira

By   /  Friday, March 24th, 2017  /  Health Care & Life Science, Latest news  /  Comments Off on Amgen gets European approval for biosimilar of Humira

Thousand Oaks-based Amgen has announced that the European Commission has granted marketing authorization for Amgevita, a drug that treats inflammatory diseases, including moderate-to-severe rheumatoid arthritis. The Amgen biosimilar will compete with AbbVie’s blockbuster drug Humira. “The approval of our first biosimilar by the European Commission is a major milestone not just for Amgen as a company, but for the millions Read More →

Latest

Europeans recommend approval of Amgen’s biosimilar of AbbVie’s Humira

By   /  Friday, January 27th, 2017  /  Health Care & Life Science, Latest news, Technology  /  Comments Off on Europeans recommend approval of Amgen’s biosimilar of AbbVie’s Humira

The European Medicines Agency recommended the approval of the ABP 501, a biosimilar of AbbVie’s Humira (adalimumab), for treatment of inflammatory diseases, Thousand Oaks-based biotech company Amgen announced on Jan. 27. The EMA recommended ABP 501’s use for moderate-to-severe rheumatoid arthritis, psoriatic arthritis, severe ankylosing spondylitis, severe axial spondyloarthritis without radiographic evidence of AS, moderate-to-severe Read More →

Latest

Amgen’s Humira biosimilar delayed, Enbrel approved

By   /  Thursday, November 10th, 2016  /  Health Care & Life Science, Latest news, Technology  /  Comments Off on Amgen’s Humira biosimilar delayed, Enbrel approved

Amgen’s Humira biosimilar Amjevita will be delayed at least through 2017 due to litigation by competitor AbbVie. The maker of Humira filed a patent infringement claim against Amgen on Aug. 4, alleging that the drug also violates the Biosimilar Price Competition and Innovation Act. Amgen was approved to market its biosimilar Sept. 23 by the Read More →

Latest

Amgen spends big to defeat Proposition 61

By   /  Friday, October 14th, 2016  /  Health Care & Life Science, Law & Goverment, Top Stories, Top Story  /  Comments Off on Amgen spends big to defeat Proposition 61

This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.